OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings

OS Therapies on Tuesday said it expects to complete conditional Marketing Authorization Application (MAA) submissions to both the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) by the end of the first quarter of 2026.Additionally, the company is on track to submit the Clinical BLA module to the FDA following a Type D meeting anticipated in March 2026.The company is also preparing to release additional biomarker data from its Human Metastatic Osteosa ...